Licensed rights and other intangible assets (Tables)

12 Months Ended

Dec. 31, 2021

Goodwill And Intangible Assets Disclosure [Abstract]

Summary of Information about License Rights and Other Intangible Assets, Net

The following provides information about our license rights and other intangible assets, net (in thousands):

	As of December 31, 2021						As of December 31, 2020
	Gross						Gross
	Carrying		Accumulated				Carrying		Accumulated
	Amount		Amortization		Net		Amount		Amortization		Net
License rights and other intangible assets    subject to amortization:
License rights	$	40,000	$	6,826	$	33,174	$	40,000	$	3,803	$	36,197
Hormone therapy drug patents		5,834		1,042		4,792		4,045		749		3,296
Hormone therapy drug patents applied    and pending approval		2,020		—		2,020		1,629		—		1,629
License rights and other intangible assets    subject to amortization		47,854		7,868		39,986		45,674		4,552		41,122
Intangible assets not subject to amortization:
Trademarks/trade name rights		332		—		332		323		—		323
License rights and other intangible assets, net	$	48,186	$	7,868	$	40,318	$	45,997	$	4,552	$	41,445

Summary of License Rights And Other Intangible Assets Subject To Amortization Is Expected To Be Amortized

Our license rights and other intangible assets subject to amortization is expected to be amortized as follows (in thousands):

Year ending December 31,
2022	$	3,451
2023		3,445
2024		3,447
2025		3,445
2026		3,445
Thereafter		20,733
Total	$	37,966